Trial Profile
A MULTICENTER, OPEN LABEL PHASE I/II STUDY OF CARFILZOMIB, POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 29 Jun 2023 Status changed from active, no longer recruiting to completed.
- 24 Mar 2022 Planned End Date changed from 1 Jun 2022 to 1 Sep 2022.
- 02 Feb 2021 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.